Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 11/20 | 0.60 |
| ▸ | MGLL | Q99685 | 11/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL425817 | 0.84 | FAAH (0.69) | FAAHMGLL | |
| SCHEMBL5967891 | 0.84 | FAAH (0.58) | FAAHMGLL | |
| SCHEMBL5641463 | 0.82 | FAAH (0.74) | FAAHMGLL | |
| SCHEMBL5641853 | 0.81 | FAAH (0.69) | FAAHMGLL | |
| SCHEMBL425638 | 0.81 | FAAH (0.65) | FAAHMGLL | |
| SCHEMBL5641596 | 0.80 | FAAH (0.67) | FAAHMGLL | |
| SCHEMBL5642456 | 0.80 | FAAH (0.63) | FAAHMGLL | |
| SCHEMBL427655 | 0.79 | FAAH (0.69) | FAAHMGLL | |
| SCHEMBL19357103 | 0.78 | FAAH (0.81) | FAAHMGLL | |
| SCHEMBL5639585 | 0.78 | FAAH (0.67) | FAAHMGLL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9353082-B2 | Pharmaceutical compounds | BIAL—PORTELA & CA, S.A. (PT) | 2016-05-31 | — | — | US | disclosed |
| US-9353082-B2 | Pharmaceutical compounds | BIAL—PORTELA & CA, S.A. (PT) | 2016-05-31 | — | — | US | disclosed |
| US-9353082-B2 | Pharmaceutical compounds | BIAL—PORTELA & CA, S.A. (PT) | 2016-05-31 | — | — | US | disclosed |
| US-20120065191-A1 | PHARMACEUTICAL COMPOUNDS | BIAL - PORTELA & Cª, S.A. (PT) | 2012-03-15 | — | — | US | disclosed |
| US-20120065191-A1 | PHARMACEUTICAL COMPOUNDS | BIAL - PORTELA & Cª, S.A. (PT) | 2012-03-15 | — | — | US | disclosed |
| US-20120065191-A1 | PHARMACEUTICAL COMPOUNDS | BIAL - PORTELA & Cª, S.A. (PT) | 2012-03-15 | — | — | US | disclosed |
| WO-2010074588-A2 | PHARMACEUTICAL COMPOUNDS | BIAL - PORTELA & Cª, S.A. (PT) | 2010-07-01 | — | — | WO | disclosed |
| US-7208504-B2 | Bicyclic inhibitors of hormone sensitive lipase | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-04-24 | — | — | US | disclosed |
| US-7208504-B2 | Bicyclic inhibitors of hormone sensitive lipase | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-04-24 | — | — | US | disclosed |
| US-7208504-B2 | Bicyclic inhibitors of hormone sensitive lipase | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-04-24 | — | — | US | disclosed |
| US-20040127484-A1 | Novel bicyclic inhibitors of hormone sensitive lipase | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065191-A1 | PHARMACEUTICAL COMPOUNDS | FAAH, FAAH2, ASAH1 | FAAH 1/4885MGLL 11/4885KDM4E 1982/4885 |
| US-20040127484-A1 | Novel bicyclic inhibitors of hormone sensitive lipase | LIPE, PNLIP, CEL | FAAH 144/4885MGLL 20/4885KDM4E 2337/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.